SCHEMBL1027998

SCHEMBL1027998

CC(C)CNC(=O)O[C@H]1CCC[C@@H]1N1C(=O)C=CC1=O

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.37
MEN1 O00255 2/20 0.37
EPHX1 P07099 1/20 0.35
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CHRM2 P08172 3/20 0.32
CHRM4 P08173 3/20 0.32
CHRM1 P11229 3/20 0.32
CHRM3 P20309 3/20 0.32
MMP1 P03956 1/20 0.32
MMP8 P22894 1/20 0.32
EPHX2 P34913 1/20 0.31
PLAT P00750 1/20 0.31
ADCY1 Q08828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1028431 0.85 EPHX1 (0.45) MEN1EPHX1SMN1; SMN2CHRM2CHRM4
SCHEMBL1026369 0.84 CYP3A4 (0.36) SMN1; SMN2CHRM2CHRM4CHRM1CHRM3
SCHEMBL1029351 0.83 BCHE (0.46) KMT2AMEN1EPHX1KDM4E
SCHEMBL1026748 0.81 BCHE (0.48) HSD17B10
SCHEMBL1026256 0.81 CHRM1 (0.44) MEN1CHRM2CHRM4CHRM1CHRM3
SCHEMBL1027822 0.80 CHRM2 (0.39) KMT2AMEN1CHRM2CHRM4CHRM1
SCHEMBL1028614 0.78 CHRM2 (0.35) KMT2AMEN1CHRM2CHRM4CHRM1
SCHEMBL1024756 0.78 BCHE (0.53)
SCHEMBL1027856 0.77 NTMT1 (0.36) SMN1; SMN2CHRM2CHRM4CHRM1CHRM3
SCHEMBL1074002 0.77 TAAR1 (0.44) KMT2AMEN1EPHX1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479669-B1 Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography TOSOH CORP (JP) 2011-01-19 EP disclosed
US-7645889-B2 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2010-01-12 US disclosed
US-20080230482-A1 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2008-09-25 US disclosed
US-7381742-B2 Optically active polymaleimide derivatives and process for their production TOSOH CORPORATION (JP) 2008-06-03 US disclosed
US-20070131616-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2007-06-14 US disclosed
US-7186750-B2 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2007-03-06 US disclosed
US-20040235937-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them TOSOH CORPORATION (JP) 2004-11-25 US disclosed
EP-1479669-A1 Optically active maleimide derivatives and polymaleimides for use as chiral adsorbent in chromatography Tosoh Corporation (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080230482-A1 Optically active polymaleimide derivatives and process for their production CYBA, COASY, MEP1B KMT2A 3220/4885MEN1 211/4885EPHX1 4075/4885
US-20040235937-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them MACF1, MEP1B, CYBA KMT2A 2453/4885MEN1 55/4885EPHX1 4267/4885
US-20070131616-A1 Optically active maleimide derivatives, optically active polymaleimide derivatives, process for their production, separating media comprising the optically active polymaleimide derivatives and method of separating optically active compounds using them MACF1, MEP1B, ACMSD KMT2A 2367/4885MEN1 75/4885EPHX1 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.